All Reports

South African HIV Investment Case : 2021 Full report

Since 2016, annual updates of the HIV Investment Case set out to determine the optimal package of HIV interventions in South Africa, with the aim improve allocative efficiency of HIV funding from the three main sources- the South African government, PEPFAR and the Global Fund. The 2021 HIV Investment Case had the following central additions: For the 95% retention scenario in, we included a hypothetical ART retention intervention that aimed at reaching the UNAIDS target of 95% ART coverage. We 

COVID-19 modelling update: Considerations for a potential fourth wave

The South African COVID-19 Modelling Consortium (SACMC), of which a number of HE2ROs are members, has released a new report about the core modelling team’s projections of a potential fourth wave of COVID-19 cases in South Africa. This report takes into account the impact of the vaccination programme, future changes on population behaviour and restriction levels, as well as a potential new variant of concern with immune escape properties. The report is available below. Additionally, the 

COVID-19 modelling update: Considerations for a potential third wave

The South African COVID-19 Modelling Consortium (SACMC), of which a number of HE2ROs are members, has released a new report about the core modelling team's projections of a potential third wave of COVID-19 cases in South Africa. This report takes into account the impact of the Delta variant and the progress of the vaccination programme. The report is available below. Additionally, the day-to-day development in case numbers, hospital admissions and deaths can be tracked on 

The Path From Evidence to Policy Change: Supporting the development of the South African HIV response – Step 1 Identifying the Problem: The HIV Care Cascade

In September 2016, South Africa adopted WHO recommendations to eliminate CD4 thresholds for ART initiation. As part of our commitment to support the South African Government, HE2RO assessed the country-specific implications of these international recommendations. In this step, we show how a team of investigators from HE2RO and Boston University identified shortcomings in the HIV Care Cascade and used country-specific data to inform the local HIV 

Behavioural interventions and nudges to support HIV care continuity during COVID-19: A guide for programs, policymakers and researchers

The COVID-19 crisis poses new, and compounds existing challenges to ongoing efforts to combat HIV/AIDS in high prevalence countries, where the expansion of HIV services has saved millions of lives and reduced new HIV infections. Behavioural interventions that address the barriers faced by patients and providers can help sustain this progress and further improve HIV prevention and treatment outcomes.This document provides examples of behavioural insights that can be used to address specific 

Estimating cases for COVID-19 in South Africa Long-term national projections Report Update: 6 May 2020

We are pleased to announce that we are now able to share the reports on the projections of the National Covid-19 Epi Model to which a number of HE2ROs have contributed. The long-term national and provincial reports are available here. They will be updated about once a month. Over the last eight weeks, Gesine Meyer-Rath, Lise Jamieson, Brooke Nichols, Jacqui Miot and Kerensa Govender have been working with the National Department of Health (NDoH) and National Treasury to aid decision making 

Estimating cases for COVID-19 in South Africa Long-term provincial projections Report Update: 6 May 2020

We are pleased to announce that we are now able to share the reports on the projections of the National Covid-19 Epi Model to which a number of HE2ROs have contributed. The long-term national and provincial reports are available here. They will be updated about once a month. Over the last eight weeks, Gesine Meyer-Rath, Lise Jamieson, Brooke Nichols, Jacqui Miot and Kerensa Govender have been working with the National Department of Health (NDoH) and National Treasury to aid decision making 

Differentiated models of service delivery (DSD) for antiretroviral treatment of HIV in subSaharan Africa: A review of the gray literature as of June 2019 AMBIT Project Report Number 03

To achieve global targets for the treatment and prevention of HIV, most high prevalence countries are working towards scaling up alternative service delivery approaches, or differentiated service delivery (DSD) models. DSD models aim to achieve a number of potential benefits to both providers and patients, including better clinical outcomes, greater patient satisfaction, lower cost, and more efficient and convenient service delivery. To date, most DSD model development and implementation has 

Provider costs associated with differentiated models of service delivery for HIV treatment in Sub-Saharan Africa AMBIT Project Report Number 02

According to the most recent estimates, 16.4 million people are receiving antiretroviral therapy (ART) for HIV in sub-Saharan Africa.1 Global “90-90-90” targets for HIV diagnosis, treatment, and viral suppression call for universal access and rapid-scale-up of treatment coverage, which would require another 3 million patients to be added to the national HIV treatment programs in eastern and southern Africa.1 Meanwhile, donor spending in low and middle-income countries has declined over the 

Patient benefits and costs associated with differentiated models of service delivery for HIV treatment in Sub-Saharan Africa AMBIT Project Report Number 01

Costs and benefits of DSDs to patients themselves (as opposed to costs and benefits to providers and funders) are often omitted from evaluations of specific models of service delivery and from mathematical modeling of potential impact. As part of a larger rapid review of the published and gray literature on the outcomes of DSDs since 2016, in this report we present and discuss the subset of sources that provide empirical information on patient costs and benefits and the acceptability of DSDs 

Consolidated spending on HIV and TB in South Africa (2014/15–2016/17)

This review of HIV and TB expenditure in South Africa is an input to policy, planning and management processes within and amongst spheres of government and between government and development partners. The data have been especially useful to national and provincial programme managers as they perform their oversight functions, leading to improved spending of available resources. With 52 annexes, it also serves as an authoritative reference document detailing levels and trends in HIV and TB